BIDU enters September with short interest still elevated from last week's post-earnings rebuild, but the lending market has begun to loosen — a quiet divergence from the tight conditions that defined late August.
The short position that jumped so abruptly on August 25 has held its ground without extending further. Borrowed shares are running near 10.8–11.2 million, broadly unchanged from the peak reached after the Q2 print, and up roughly 30% on the week as the prior Tuesday's lower base rolls out of the calculation. What has shifted is availability: at 117%, the lending pool is markedly more relaxed than the 83% tightness seen last Tuesday. That loosening has come alongside a drop in borrow cost, down 21% on the week to 0.65% — already low in absolute terms and now drifting lower. The ORTEX short score has eased slightly to 55.8 from 57.3 a week ago, consistent with a short position that is consolidating rather than pressing. Together, the picture is one of shorts holding their positions but no fresh wave of new conviction entering the borrow market.
Options positioning confirms the same constructive-but-cautious tilt that was already visible last week. The put/call ratio is at 0.57, roughly 0.76 standard deviations below its 20-day average of 0.61, keeping calls dominant. That continues the rotation away from the heavy put loading seen in early August when the PCR was running near its 52-week high of 0.69. The options market and the borrow market are not sending the same signal — shorts are holding large positions, but options traders are not hedging as aggressively as they were a month ago. That contrast is the defining tension in BIDU's current setup.
The Street has moved decisively in one direction since the earnings release. Morgan Stanley cut its rating to Underweight on August 19 — the lone outright downgrade — while Barclays held Equal-Weight but trimmed its target from $124 to $96, now sitting essentially at the current price of $94.86. Susquehanna shaved its Neutral target from $140 to $105 last week. Benchmark kept its Buy but slashed its target from $215 to $150. The common thread is not a change in view but a reality-check on valuation: core advertising revenue fell 15% year-over-year, and most analysts now model only modest recovery in FY26. The bull case rests on AI Cloud growing 34% and AI-native marketing surging, but those businesses have not yet offset the structural ad decline. The PE multiple of 13.3x and EV/EBITDA of 8.8x look undemanding on paper, but the earnings momentum factor scores — 17th percentile on a 30-day basis, 19th percentile over 90 days — suggest the Street is still cutting numbers, not raising them. The EPS surprise score at the 91st percentile is the one genuine bright spot: when Baidu does beat, it tends to beat clearly.
Capital Research and Management made the most notable institutional move in the latest reporting window, adding over 2.2 million shares to bring its position to 8.6 million — a sizeable addition relative to the fund's prior holding. BlackRock and Vanguard both added modest amounts. Founder and CEO Robin Li holds just under 20% of the company and the recent trades on record are all compensation awards, not open-market activity, so there is no insider buying signal to read into the current dip.
The stock is off 14.6% for the month and down roughly 26% year-to-date, underperforming most of its Chinese internet peers. Close peer BILI fell another 4.7% on the week and is itself under pressure, while Autohome (ATHM) has been more resilient, gaining 1.7%. The next earnings event is not scheduled until November 18, leaving the stock to trade on macro China sentiment and any interim AI product updates in the interim.
The question for the weeks ahead is whether the borrow market's loosening signals that the post-earnings short rebuild has run its course — or whether it simply reflects the pool replenishing ahead of another potential leg lower.
See the live data behind this article on ORTEX.
Open BIDU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
